The Absorption, Distribution, Metabolism and Excretion of Riccardin D in Rats

 

 Buy Article Permissions and Reprints

Abstract

The present study was designed to investigate the pharmacokinetics following oral and intravenous administration of Riccardin D, an anticancer drug candidate isolated from Chinese liverworts Dumortiera hirsute, in Wistar rats. An HPLC-MS/MS analytical method was developed and validated. The results demonstrated that Riccardin D’s bioavailability was 13.4%, 11.4%, and 9.8% after oral administration at 20 mg/kg, 40 mg/kg, and 80 mg/kg, respectively. There was no significant difference in the elimination half-time of Riccardin D at these doses, suggesting that Riccardin D may have linear pharmacokinetic characteristics in rats. The metabolite of Riccardin D in rat was identified as the glucuronide of Riccardin D. Riccardin D showed a wide distribution in various tissues followed by a rapid elimination from most of the tissues tested. Riccardin D was found to distribute widely in the tissues 0.5 h after oral and intravenous administration. The tissue concentrations were markedly decreased 8 h and 6 h after oral and intravenous dosing, respectively. Both Riccardin D and its conjugated metabolite were detected in urine and bile samples while only Riccardin D was detected in feces. Taken together, the study provided valuable pharmacokinetic data for further drug development of Riccardin D.

• References

• 1 Lu ZQ, Fan PH, Ji M et al. Terpenoids and bisbibenzyls from Chinese liverworts Conocephalum conicum and Dumortiera hirsute. Journal of Asian Natural Products Research 2006; 8: 187-192
  CrossrefPubMedGoogle Scholar
• 2 Jiang J, Sun B, Wang YY et al. Synthesis of macrocyclic bisbibenzyl derivatives and their anticancer effects as anti-tubulin agents. Bioorganic & Medicinal Chemistry 2012; 20: 2382-2391
  CrossrefPubMedGoogle Scholar
• 3 Xue X, Qu XJ, Gao ZH et al. Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II. Invest New Drugs 2012; 30: 212-222
  CrossrefPubMedGoogle Scholar
• 4 Sun CC, Zhang YS, Xue X et al. Inhibition of angiogenesis involves in anticancer activity of riccardin D, a macrocyclic bisbibenzyl, in human lung carcinoma. European Journal of Pharmacology 2011; 667: 136-143
  CrossrefPubMedGoogle Scholar
• 5 Xue X, Sun DF, Sun CC et al. Inhibitory effect of riccardin D on growth of human non-small cell lung cancer in vitro and in vivo studies. Lung Cancer 2012; 76: 300- 308
  CrossrefPubMedGoogle Scholar
• 6 Liu HP, Gao ZH, Cui SX et al. Inhibition of Intestinal Adenoma Formation in APCMin/+Mice by Riccardin D, a Natural Product Derived from Liverwort Plant Dumortiera hirsute. PLoS One 2012; 7: e33243
  CrossrefPubMedGoogle Scholar
• 7 Xing J, Lv BB, Xie CF et al. Liquid chromatography-tandem mass spectrometry assay for the quantitation of plagiochin E and its main metabolite plagiochin E glucuronides in rat plasma. Journal of Pharmaceutical and Biomedical Analysis 2008; 47: 949-953
  CrossrefPubMedGoogle Scholar